Scientific and Medical Services Leadership

Dr. Zaim has over 25 years of medical imaging experience in both academic and service-related organizations, leading medical and scientific teams as they deliver critical imaging support to the worldwide biopharmaceutical industry. He is a board-certified radiologist with subject matter expertise in imaging biomarkers across a broad array of therapeutic areas.

Dr. Bohnsack is a board-certified radiologist with clinical experience in both EU and USA. For 20+ years he’s been reputably positioned at the forefront of oncology imaging advances in the clinical trial industry. He co-authored irRC in 2007 and published irRECIST in 2014 which were subsequently validated in February 2022. Both criteria remain the gold standard in solid-tumor oncology and especially I-O imaging. Oliver earned his M.D. from the University of Essen, Germany, his MBA in Healthcare Management from the University of California and his PhD in Radiology, Radiation Modulation and Reduction in CT at the University of Munich.

Dr. Rohit Sood has contributed as a scientific lead on over 160 imaging clinical trials spanning the entire spectrum, from early to late phase, across multiple therapeutic areas including more than 40 in neurological indications. He has contributed to the science on several Neuro-oncology, Neurodegenerative, Neuropsychiatry and Rare disease clinical trials and has collaborated with our study sponsors to develop criteria for evaluating the eligibility, efficacy, and safety aspects of their studies. As a senior member of several scientific organizations and societies, Dr. Sood is actively engaged in furthering the science in the clinical trial space.

An acknowledged expert in neuroimaging of Alzheimer’s Disease (AD) and other forms of dementia, Prof. Cash brings 20 years of experience to Perceptive. He actively participates on various national and international committees, including DIAN, ADNI, GENFI, and has led the ISTAART Neuroimaging PIA, an organization of over 1700 neuroimaging researchers working in dementia. His research focuses on identifying early signs and characterizing the preclinical stages of dementias and how these changes can better inform clinical trials. He has set up, managed, and analyzed numerous large-scale multi-center studies analyzing biomarkers and brain imaging data.

Dr. Jarecha’s expertise in managing the imaging components of more than 300 oncology and haemato-oncology clinical trials resulted in the submission and approval of more than 20 regional and global oncology indication treatments. Building strong teams in the USA and APAC, he manages the USA, China, and Japan markets’ unique drug development challenges. A board-certified Radiologist, Rudresh served as Co-Chair of a CT Coordinating Committee and CT Volumetry Biomarker Committee in QIBA, RSNA.

Dr. Shao is a Senior Medical Director and Scientific leader of APAC in Perceptive. She has more than 10 years of experiences in medical imaging in clinical research and supported over 100 clinical trials in Oncology which obtained approvals across global regulatory agencies in particular in China. She was the first member of the scientific team of perceptive in Shanghai where she built and led the Scientific and Medical team in China to serve the unique and dynamic requirements of the market across multiple therapeutic areas.